Mauna Kea Technologies Bolsters Endomicroscopy IP with New AI Patent

Mauna Kea Technologies, based in Paris and Boston, has received its 13th U.S. patent for an AI-based enhancement of Confocal Laser Endomicroscopy (CLE). This patent, codenamed "AURA", enhances the intellectual property of Mauna Kea's Cellvizio® platform, focusing on real-time AI integration.

This development aims to improve the interface and efficiency of their endomicroscopy technology in clinical settings, which could facilitate its adoption across various medical fields. The AURA portfolio complements an existing set of patents known as "EVA", centered around AI-driven image processing.

This follows a strategic partnership with V7, a UK-based AI company, to enhance data quality for endomicroscopy uses. Sacha Loiseau, Chairman and CEO, highlighted the integration of AURA and EVA as a crucial advancement in AI-assisted cellular imaging.